40, Dalton St

Boston,

MA,

USA,

ZIP: 02115

Phone: +1 617 455 4188

Whilst PROTACs continue to make headwind, much of the heterobifunctional and monovalent opportunity beyond the ubiquitin proteosome system remains untapped, drawing in new and distinguished biopharma in the race to develop new stabilization, modulation, post-translational modification, and inactivation/activation modalities. Taking on this emerging proximity phenomenon is no easy feat as knowledge gaps persist in validating novel mechanisms of action, accessing diverse chemical matter, and rationally designing selective and potent small molecules and biologics for novel target spaces.

Owing to this, the 4th Annual Induced Proximity-Based Drug Discovery Summit returns as the definitive and first established forum dedicated to gaining proof of concept for protein stabilization, modulation and post-translational modification.

As the community makes early strides, answer your burning questions with data-driven presentations, technical discussions, and interactive sessions as we unite 100+ induced proximity experts devoted to exploring the application of induced proximity in diverse fields in and beyond protein degradation.

URLs:
Tickets: https://go.evvnt.com/2313820-2?pid=1052
Brochure: https://go.evvnt.com/2313820-3?pid=1052

Prices:
Conference + 2 Workshops (Drug Developer Pricing): USD 4197.00,
Conference + 1 Workshop (Drug Developer Pricing): USD 3598.00,
Conference Only (Drug Developer Pricing): USD 2999.00,
Conference + 2 Workshops (Research Institute Pricing): USD 3597.00,
Conference + 1 Workshop (Research Institute Pricing): USD 3098.00,
Conference Only (Research Institute Pricing): USD 2599.00,
Conference + 2 Workshops (Service Provider Pricing): USD 5097.00,
Conference + 1 Workshop (Service Provider Pricing): USD 4398.00,
Conference Only (Service Provider Pricing): USD 3699.00

Andrew Zhang, Director, Chemical Biology, AstraZeneca, Brandon Turunen, Co-Founder and Chief Technology Officer, Solu Therapeutics, Changhoon Ji, Executive Director, AUTOTAC Bio, Charles Y., Lin Senior Vice President - Research and Development, Kronos Bio, Christian Munch, Professor and Director of Proteomics, Goethe University Frankfurt, Christopher Phelps, Senior Vice President and Head of Early Drug Discovery, Nurix Therapeutics, Edmund Graziani, Chief Executive Officer, Apertor Pharmaceuticals, Heidi Greulich, Senior Group Leader, The Broad Institute of MIT and Harvard, Jun Qi, Assistant Professor – Medicine, Dana-Farber Cancer Institute, Kathleen Seyb, Senior Vice President - Biology and Translational Sciences, TRIANA Biomedicines, Katie Spooner, Research Analyst, Beacon, Kelly Rainbolt, Senior Scientist - Biochemical and Cellular Engineering, Lyterian Therapeutics, Lokesh Gakhar, Senior Director and Head of Structural Biology and Protein Sciences, PAQ Therapeutics, Matthew Hayward, Vice President of Drug Discovery, Magnet Biomedicine, Moses Moustakim, Senior Scientist - Chemistry, Photys Therapeutics, Rick Ewing, Vice President and Head of Chemistry, Rapafusyn Pharmaceuticals, Shyra Gardai, Chief Scientific Officer, EpiBiologics, Sriram Subramaniam, Chief Executive Officer and Founder, Gandeeva Therapeutics, Thomas Pillow, Senior Scientist, Genentech, Trevor Zandi, Postdoctoral Scientist, Novartis Biomedical Research, Tyzoon Nomanbhoy, Vice President, Chemical Biology, Vicinitas Therapeutics